The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
In this press briefing, Jesse Tettero, MD, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands & Virginia Tech FBRI Cancer Research Center, Washington, DC, presents an analysis which validated the use of measurable residual disease (MRD) as a surrogate endpoint in acute myeloid leukemia (AML) using harmonized patient-level data from seven prospective randomized trials collected through the HARMONY Alliance. This press briefing took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
